Alpha Tau Medical Ltd. DRTS
Regular-session close
After hours · Nov 19, 6:11 PM ET
- YTD
- +128.48%
- 1 year
- +207.34%
5D -2.09 (-15.60%)
- Market cap
- 1.05B
- EPS (ttm)
- -1.04
- Shares out
- 92.48M
- Forward P/E
- -21.00
- YTD return
- +128.48%
- 1-year return
- +207.34%
- 50-day average
- 13.90
- 200-day average
- 10.99
- Enterprise value
- 1.02B
- Volume
- 1.27M
- Avg volume
- 577.54K
- Open
- 12.08
- Previous close
- 12.01
- Day's range
- 10.89 – 12.17
- 52-week range
- 3.43 – 15.79
- Beta
- 1.29
- Analysts
- Strong Buy
- Price target
- 20.60 (+82.1%)
Key statistics
- Price / book
- 23.71
- Free cash flow
- -20.26M
- Total cash
- 100.64M
- Total debt
- 15.15M
- Return on equity
- -141.68%
- Short % of float
- 6.10%
Fundamental scorecard
3 of 25 checks passed on DRTS’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2026 | Sep 30, 2026 | -0.15 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.14088 | -0.50 | -0.36 | -254.91% |
| May 18, 2026 | Mar 31, 2026 | -0.13 | -0.26 | -0.13 | -100.00% |
| Mar 9, 2026 | Dec 31, 2025 | -0.13 | -0.14 | -0.01 | -7.69% |
| Nov 20, 2025 | Sep 30, 2025 | -0.12 | -0.14 | -0.02 | -16.67% |
| Aug 11, 2025 | Jun 30, 2025 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Piper Sandler | up | Neutral | Overweight |
| Oct 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2026 | Barclays | main | Overweight | Overweight |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 22, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- alphatau.com
News
Alpha Tau Medical Q3 EPS $(0.33) Misses $(0.15) Estimate
Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Medical: The Rubber Meets The Road In H1 2027 HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target
Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript
Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Take-Two Interactive Software Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events
Your note
Sign in to keep a note on DRTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LEVY RAPHI | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 20, 2026 | 90,180 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gem Investment Advisors, LLC | 2.07% | 1,434,476 | 16.22M | Sep 29, 2026 |
| Blackrock Inc. | 2.01% | 1,395,251 | 15.78M | Sep 29, 2026 |
| UBS Group AG | 1.81% | 1,257,198 | 14.22M | Sep 29, 2026 |
| HighTower Advisors, LLC | 1.29% | 894,043 | 10.11M | Sep 29, 2026 |
| Boothbay Fund Management, LLC | 1.12% | 773,196 | 8.74M | Sep 29, 2026 |
| Pier Capital, LLC | 1.05% | 730,208 | 8.26M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core MSCI EAFE ETF | 0.68% | 470,946 | 5.33M | Sep 29, 2026 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 0.31% | 217,272 | 2.46M | Sep 29, 2026 |
| ARK ETF Trust-ARK Israel Innovative Technology ETF | 0.22% | 155,016 | 1.75M | Oct 30, 2026 |
| iShares, Inc.-iShares MSCI Israel ETF | 0.19% | 133,302 | 1.51M | Sep 29, 2026 |
| RBB Fund, Inc.-Adara Smaller Companies Fund | 0.19% | 134,468 | 1.52M | Oct 30, 2026 |
| Dunham Funds-Dunham Small Cap Growth Fund | 0.10% | 71,660 | 810.47K | Jul 30, 2026 |
